A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines

被引:12
|
作者
Punga, Anna Rostedt [1 ]
Alimohammadi, Mohammad [2 ]
Fagrell, Dan [3 ]
Nyberg, Frida [4 ]
Rees, Diane [5 ]
Wong, Cindy [4 ]
机构
[1] Uppsala Univ, Dept Neurosci, Husargatan 3, S-75124 Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[3] Goteborgs Plastikkirurgiska Ctr, Gothenburg, Sweden
[4] Galderma A&C, Uppsala, Sweden
[5] Zenith Healthcare Commun Ltd, Chester, Cheshire, England
关键词
TOXIN TYPE-A; DOUBLE-BLIND; BOTULINUM; DIFFUSION; RHYTIDES;
D O I
10.1097/DSS.0000000000000805
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUNDDifferent volumes of 0.9% NaCl may be used to reconstitute abobotulinumtoxinA yielding an injection volume that ranges from 0.05 to 0.1 mL per injection point for treatment of glabellar lines.OBJECTIVETo evaluate the efficacy, safety, and subject satisfaction of 2 different injection volumes to deliver the same unit dose of abobotulinumtoxinA for treatment of glabellar lines.MATERIALS AND METHODSThis randomized comparative study was conducted using 2 different reconstitution volumes to deliver a fixed unit dose of 10 Speywood units (sU) of abobotulinumtoxinA in either 0.05 mL (labeled volume) or 0.1 mL (twofold volume) per injection point. Evaluations included wrinkle severity, neurophysiological assessment by compound muscle action potential (CMAP), and subject satisfaction.RESULTSUse of either injection volume of abobotulinumtoxinA resulted in the early onset of effect, high effectiveness, and long duration of effect. The safety profile and injection pain levels were similar in both groups. The twofold injection volume was shown to be noninferior to the labeled injection volume based on CMAP results.CONCLUSIONA twofold increase in injection volume to 0.1 mL per injection point to deliver 10 sU of abobotulinumtoxinA is effective and safe.
引用
收藏
页码:967 / 976
页数:10
相关论文
共 50 条
  • [41] Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study
    Delgado, Mauricio R.
    Tilton, Ann
    Carranza-Del Rio, Jorge
    Dursun, Nigar
    Bonikowski, Marcin
    Aydin, Resa
    Maciag-Tymecka, Iwona
    Oleszek, Joyce
    Dabrowski, Edward
    Grandoulier, Anne-Sophie
    Picaut, Philippe
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2021, 63 (05): : 592 - U14
  • [42] Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized study
    Lowe, N
    Lowe, P
    Patnaik, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB42 - AB42
  • [43] Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial
    Ascher, Benjamin
    Kestemont, Philippe
    Boineau, Dominique
    Bodokh, Isaac
    Stein, Annette
    Heckmann, Marc
    Dendorfer, Markus
    Pavicic, Tatjana
    Volteau, Magali
    Tse, Anissa
    Picaut, Philippe
    Rzany, Berthold
    AESTHETIC SURGERY JOURNAL, 2018, 38 (02) : 183 - 191
  • [44] Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study
    Kestemont, Philippe
    Hilton, Said
    Andriopoulos, Bill
    Prygova, Inna
    Thompson, Catherine
    Volteau, Magali
    Ascher, Benjamin
    AESTHETIC SURGERY JOURNAL, 2022, 42 (03) : 301 - 313
  • [45] Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: A randomized, double-blinded, active controlled multicenter study
    Lee, W. S.
    Won, C. H.
    Huh, C. H.
    Kang, H.
    Kim, B. J.
    Lee, J. H.
    Kim, W. S.
    TOXICON, 2013, 68 : 116 - 116
  • [46] Efficacy and Safety of OnabotulinumtoxinA for Treating Crow's Feet Lines Alone or in Combination With Glabellar Lines: A Multicenter, Randomized, Controlled Trial
    Moers-Carpi, Marion
    Carruthers, Jean
    Fagien, Steven
    Lupo, Mary
    Delmar, Henry
    Jones, Derek
    Somogyi, Christine
    Lee, Elisabeth
    Lei, Xiaofang
    MacKinnon, Suzanne
    Davis, Paula G.
    Yalamanchili, Ramana
    Campo, Antoinette
    Beddingfield, Frederick C., III
    DERMATOLOGIC SURGERY, 2015, 41 (01) : 102 - 112
  • [47] Comparing the efficacy, safety, and satisfaction for moderate to severe glabellar frown lines between abobotulinum toxin A and incobotulinum toxin A: a multicenter randomized study
    Lee, Jong Hun
    Lee, Seo Koo
    Kim, Sang Hun
    Lee, Sun Jae
    Kim, Jun Hyun
    Park, Eun Soo
    ARCHIVES OF AESTHETIC PLASTIC SURGERY, 2024, 30 (03): : 101 - 107
  • [48] Efficacy and Safety of IncobotulinumtoxinA in Asian Subjects: A Pooled Analysis of Clinical Trials in the Treatment of Glabellar Frown Lines
    Seo, Kyle
    Tsai, Tsen-Fang
    Chao, Yates Yen-Yu
    Goodman, Greg J.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (09) : 1084 - 1087
  • [49] A Two-Center, Open-Label, Randomized, Split-Face Study to Assess the Efficacy and Safety of One Versus Three Intradermal Injection Sites of AbobotulinumtoxinA in the Treatment of Lateral Periocular Rhytides
    Fabi, Sabrina G.
    Sundaram, Hema
    Guiha, Isabella
    Goldman, Mitchel P.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (08) : 932 - 937
  • [50] Commentary on A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines
    Hausauer, Amelia K.
    DERMATOLOGIC SURGERY, 2021, 47 (01) : 47 - 47